Leerink upgraded Bristol Myers (BMY) to Outperform from Market Perform with a $73 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
- AbbVie under pressure as schizophrenia drug fails two trials
- Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers
- JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news
- AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist